Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels Miguel L. Stein, MD, Joyce M. Villanueva,

Slides:

Advertisements

Similar presentations

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy

Advertisements

Comparison of the allergic and nonallergic CD4+ T-cell responses to the major dog allergen Can f 1 Suvi Parviainen, MSc, Antti Taivainen, MD, PhD, Aino.

Dorothea Dijkstra, MSc, Rob Leurs, PhD, Paul Chazot, PhD, Fiona C

Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2 Natalija Novak, MD, Nihal Mete, MD, Caroline.

Expression of IL-9 receptor α chain on human germinal center B cells modulates IgE secretion Lama M. Fawaz, PhD, Ehssan Sharif-Askari, PhD, Oumnia Hajoui,

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion

Oral immunotherapy–induced gastrointestinal symptoms and peripheral blood eosinophil responses Michael R. Goldberg, MD, PhD, Arnon Elizur, MD, Liat Nachshon,

The effects of upper respiratory infection on T-cell proliferation and steroid sensitivity of asthmatics Elcio O. Vianna, MD, PhD, Jay Westcott, PhD,

Reduced TH1/TH17 CD4 T-cell numbers are associated with impaired purified protein derivative–specific cytokine responses in patients with HIV-1 infection

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy

The role of viruses in acute exacerbations of asthma

Toll-like receptor 7–induced naive human B-cell differentiation and immunoglobulin production Mark C. Glaum, MD, PhD, Shilpi Narula, MD, Decheng Song,

Frank Kirstein, PhD, Natalie E

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Histamine H2 receptor stimulation upregulates TH2 chemokine CCL17 production in human M2a macrophages Susanne Mommert, PhD, Karl Gregor, MD, Kristine.

Distinct endotypes of steroid-resistant asthma characterized by IL-17Ahigh and IFN- γhigh immunophenotypes: Potential benefits of calcitriol Emma S. Chambers,

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis Stéphanie.

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis Friedrich Horak, MD, Kamal D.

Estrogen and progesterone decrease let-7f microRNA expression and increase IL-23/IL- 23 receptor signaling and IL-17A production in patients with severe.

Activin A and TGF-β promote TH9 cell–mediated pulmonary allergic pathology Carla P. Jones, PhD, Lisa G. Gregory, PhD, Benjamin Causton, BSc, Gaynor A.

Glucocorticoids promote intrinsic human TH17 differentiation

Dawn C. Newcomb, PhD, Madison G

Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-α John T. Schroeder, PhD,

Frank Kirstein, PhD, Natalie E

Yuichi Teraki, MD, Aika Sakurai, MD, Seiichi Izaki, MD

Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J

Allergen-induced, eotaxin-rich, proangiogenic bone marrow progenitors: A blood-borne cellular envoy for lung eosinophilia Kewal Asosingh, PhD, Jodi D.

CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis Esther Morel, PhD, Salvador Escamochero,

Neutrophils in antiretroviral therapy–controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment Laure Campillo-Gimenez,

Elevated regulatory T cells at diagnosis of Coccidioides infection associates with chronicity in pediatric patients Dan Davini, BA, Fouzia Naeem, MD,

Targeting Fel d 1 to FcγRI induces a novel variation of the TH2 response in subjects with cat allergy Kathryn E. Hulse, BS, Amanda J. Reefer, MS, Victor.

Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation Esra.

Carine Blanchard, PhD, Emily M

Alvin W. L. Schadenberg, MD, Theo van den Broek, MD, Marten A

Allison K. Martin, BS, Douglas G. Mack, PhD, Michael T

Benjamin T. Prince, MD, Msci, Ashley L. Devonshire, MD, MPH, Kristin A

Brent E. Palmer, PhD, Douglas G. Mack, PhD, Allison K

Zoulfia Allakhverdi, PhD, Michael R. Comeau, BSc, Dirk E

Novel mutation in STXBP2 prevents IL-2–induced natural killer cell cytotoxicity Rushani W. Saltzman, MD, Linda Monaco-Shawver, BA, Kejian Zhang, MD, MBA,

Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1) Kornvalee Meesilpavikkai,

Expression of IL-9 receptor α chain on human germinal center B cells modulates IgE secretion Lama M. Fawaz, PhD, Ehssan Sharif-Askari, PhD, Oumnia Hajoui,

Staphylococcal exotoxins are strong inducers of IL-22: A potential role in atopic dermatitis Margarete Niebuhr, MD, Helena Scharonow, MS, Merle Gathmann,

Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation Abel Suárez-Fueyo, PhD, Tania.

Sabah El-Ghaiesh, MSc, Joseph P

Priscilla Auyeung, PhD, Diana Mittag, PhD, Philip D

What is an “eosinophilic phenotype” of asthma?

Increased activation-induced cell death of high IFN-γ–producing TH1 cells as a mechanism of TH2 predominance in atopic diseases Tunc Akkoc, PhD, Pieter.

Persistence of natural killer cells with expansion of a hypofunctional CD56−CD16+KIR+NKG2C+ subset in a patient with atypical Janus kinase 3–deficient.

Fetal and neonatal IL-13 production during pregnancy and at birth and subsequent development of atopic symptoms Toby J. Williams, Catherine A. Jones,

Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Effect of aging on sputum inflammation and asthma control

CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study Fabien.

Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency Sayed Mahdi Marashi, PhD, Mohammed.

Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5− TH2 responses Calman Prussin, MD, Joohee Lee,

Anti–IL-5 (mepolizumab) therapy for eosinophilic esophagitis

Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis Iris M. Otani, MD, Arjun A. Anilkumar,

Dorothea Dijkstra, MSc, Rob Leurs, PhD, Paul Chazot, PhD, Fiona C

Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study

Eric B. Brandt, PhD, Melissa K. Mingler, MS, Michelle D

Cigarette smoke exposure is associated with vitamin D3 deficiencies in patients with chronic rhinosinusitis Jennifer K. Mulligan, PhD, Whitney Nagel,

IgG4 production is confined to human IL-10–producing regulatory B cells that suppress antigen-specific immune responses Willem van de Veen, MSc, Barbara.

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Carine Blanchard, PhD, Emily M

Perturbations of natural killer cell regulatory functions in respiratory allergic diseases Francesca Scordamaglia, MD, Mirna Balsamo, PhD, Antonio Scordamaglia,

Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis David W. Morris, MD, Emily M. Stucke, BA, Lisa.

Invariant natural killer T cells from children with versus without food allergy exhibit differential responsiveness to milk-derived sphingomyelin Soma.

Comparison of the allergic and nonallergic CD4+ T-cell responses to the major dog allergen Can f 1 Suvi Parviainen, MSc, Antti Taivainen, MD, PhD, Aino.

Presentation transcript:

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels Miguel L. Stein, MD, Joyce M. Villanueva, BS, Bridget K. Buckmeier, BA, Yoshiyuki Yamada, MD, Alexandra H. Filipovich, MD, Amal H. Assa'ad, MD, Marc E. Rothenberg, MD, PhD Journal of Allergy and Clinical Immunology Volume 121, Issue 6, Pages 1473-1483.e4 (June 2008) DOI: 10.1016/j.jaci.2008.02.033 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Effect of anti–IL-5 on circulating leukocytes and peripheral blood eosinophil counts. Study protocol (A) showing eosinophil responses represented by individual lines (B) and in paired individual changes before (week 8) and after (week 20) anti–IL-5 therapy (C). The percentage of eosinophils and lymphocytes (mean ± SD, n = 25) and the numbers of total white blood cell (WBC) counts expressed as × 103 cells (k) per cubic millimeter are shown (D). A dot diagram of peripheral blood eosinophil levels is shown (E). Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Plasma IL-5 levels before and after anti–IL-5 therapy. Plasma IL-5 levels represented for patients and healthy control subjects (NL; A) with paired individual changes (B) before (week 8) and after (week 20) anti–IL-5 therapy are shown. Dots under detection limit (dashed line) are extrapolated data in a log × log scale curve analysis and do not represent true values. The horizontal bars represent mean values. Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Molecular analysis of plasma IL-5. The average of subject and control samples are presented as the original IL-5 level detected at week 20 and after filtration in the upper and lower chambers (see the Methods section for details). Recombinant IL-5 at 100 pg/mL was used as a control to demonstrate that IL-5 is normally found in the lower chamber (A). The upper chamber fraction precipitation with nonsaturating quantities of protein A/G (50 μL) in representative samples and a control sample of T-cell supernatant after PHA stimulation is shown (B). A representative protein A/G dose-response curve is shown (C). The combined results of subjects' plasma (week 20) samples before and after protein A/G precipitation with saturating amounts (200 μL) is shown (D). The dashed line represents the detection limit value. Horizontal bars represent mean (SD) values (n = 12). ∗∗P < .01, ∗∗∗P < .001. Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Effect of anti–IL-5 on peripheral blood CCR3+ cell levels and the expression of IL-5Rα mcf in peripheral blood eosinophils. The percentage of CCR3+ cells in peripheral blood leukocytes (A and B) and the expression of IL-5Rα mcf (C and D) are represented as group distribution (Fig 4, A and C) and paired analysis (Fig 4, B and D) for all study subjects before (week 8) and after (week 20) anti–IL-5 therapy. The horizontal bars represent mean values. Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Effect of anti–IL-5 on intracellular IL-5 production by T cells. Anti–IL-5 therapy increased the percentage of peripheral blood CD4+ and CD8+ cells producing intracellular IL-5. The percentage of CD4+ (A and B) and CD8+ (C and D) cells producing intracellular IL-5 is shown before (week 8) and after (week 20) anti–IL-5 therapy for all study subjects. The unpaired (Fig 5, A and C) and paired (Fig 5, B and D) data are shown. The horizontal bars represent mean values. Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 6 Effect of anti–IL-5 therapy on peripheral blood eosinophil activation in response to eotaxins. Peripheral blood eosinophil activation was assessed based on eotaxin-induced eosinophil shape change ex vivo in response to eotaxin-1 (A), eotaxin-2 (B), and eotaxin-3 (C) in patients before (week 8) and after (week 20) anti–IL-5 therapy. Eosinophil shape changes in response to eotaxin-1 and eotaxin-2 are shown in a paired analysis; eosinophil shape changes in response to eotaxin-3 are shown in a nonpaired analysis. ∗P < .05, ∗∗P < .01. Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Lymphocyte and subpopulation analysis before and after anti–IL-5 therapy. The absolute lymphocyte levels and percentage of various subpopulations (percentage of CD3+, CD4+, CD8+, CD19+, and CD16+CD56+ cells) are shown for the combined cohorts before (week 8, solid bars) and after (week 20, open bars) anti–IL-5 therapy. ns, Not significant; NK, natural killer. The horizontal bars represent mean (SD) values. Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Effect of anti–IL-5 on intracellular IL-4, IL-13, IFN-γ, and TNF-α production. The percentage of peripheral blood CD4+ and CD8+ cells producing intracellular IL-4, IL-13, IFN-γ, and TNF-α after anti–IL-5 therapy is shown for the combined cohorts before (week 8) and after (week 20) anti–IL-5 therapy. ns, Not significant. Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Effect of anti–IL-5 on IL-4, IL-5, IL-10, IL-13, GM-CSF, and IFN-γ secretion by PHA-stimulated PBMCs. The secreted levels of IL-4 (A), IL-5 (B), IL-10 (C), GM-CSF (D), and IFN-γ (E) by PHA-stimulated PBMCs are shown for all cohorts before (week 8) and after (week 20) anti–IL-5 therapy. The different responses of mepolizumab on IL-13 secretion by PHA-stimulated PBMCs (F) are shown for all subjects (G) and only paired patients in cohort A (H) before (week 8) and after (week 20) anti–IL-5 therapy. Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Effect of IL-5 on IL-5Rα expression on eosinophils in vitro Effect of IL-5 on IL-5Rα expression on eosinophils in vitro. IL-5Rα mcf expression on eosinophils preincubated with a wide concentration range of IL-5 concentrations in vitro: the histogram with isotype control is shown in A. The mean value of IL-5Rα expression is shown in B (mean ± SD, n = 3). Journal of Allergy and Clinical Immunology 2008 121, 1473-1483.e4DOI: (10.1016/j.jaci.2008.02.033) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions